# A Study of FZ-AD005 in Patients With Advanced Solid Tumors

> **NCT06424665** · PHASE1 · RECRUITING · sponsor: **Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.** · enrollment: 162 (estimated)

## Conditions studied

- Advanced Solid Tumor, SCLC(Small Cell Lung Cancer) or LCNEC (Large Cell Neuroendocrine Carcinoma)

## Interventions

- **DRUG:** FZ-AD005

## Key facts

- **NCT ID:** NCT06424665
- **Lead sponsor:** Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-03
- **Primary completion:** 2026-08-01
- **Final completion:** 2027-12-01
- **Target enrollment:** 162 (ESTIMATED)
- **Last updated:** 2026-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06424665

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06424665, "A Study of FZ-AD005 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-07-29 from https://api.ai-analytics.org/clinical/NCT06424665. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*